NDA 202057 · Amarin Pharms
Vascepa
Icosapent Ethyl · Oral
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jul 26, 2012
Approved uses
2
Original approval plus efficacy supplements
Registered trials
57
21 Phase 3, 1 recruiting
FAERS reports
8,228
2,986 serious, 422 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 7, 2026.
VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels(≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. ( 1 ) as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. ( 1 ) Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. ( 1 )
Mechanism: Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity. The mechanisms of action contributing to reduction of cardiovascular events with VASCEPA (icosapent ethyl) are not completely understood but are likely multi-factorial. Increased EPA lipid composition from...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2019 Supplement 35 · Efficacy · priority review LabelLetter
- Jul 26, 2012 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewLabel
2 products under this application
- VASCEPA · ICOSAPENT ETHYL 500MG · CAPSULE, ORAL · Prescription · TE AB
- VASCEPA · ICOSAPENT ETHYL 1GM · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Icosapent Ethyl" as an intervention, any sponsor and status, largest first.
- A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk AdultsPivotal-lookingTerminated
Kaiser PermanenteAcademic, hospital or other
NCT04505098 · 39,600 participants · Start Aug 7, 2020 · Primary completion Dec 15, 2022
Drug: Icosapent ethyl · For: Covid19; Atherosclerosis; Cardiovascular Diseases and 1 more
Sites: Oakland, California
- Protective Effect of EPA on Cardiovascular EventsPivotal-lookingCompleted
Kobe UniversityIndustry
NCT00231738 · 18,000 participants · Start Nov 1996
Drug: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM) · For: Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Sites: Kobe, Japan
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinPivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01492361 · 8,179 participants · Start Nov 2011 · Primary completion May 2018
Drug: AMR101; Placebo and 1 more · For: Cardiovascular Diseases
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 410 sites in all
- PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention TrialPivotal-lookingCompleted
Estudios Clínicos Latino AméricaAcademic, hospital or other
NCT04460651 · 4,093 participants · Start Aug 14, 2020 · Primary completion Aug 30, 2021
Drug: Icosapent ethyl (IPE); Placebo · For: COVID19
Sites: Rosario, Argentina
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)Pivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01047501 · 702 participants · Start Dec 2009 · Primary completion Feb 2011
Drug: AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day and 1 more · For: Hypertriglyceridemia
Sites: Muscle Shoals, Alabama; Scottsboro, Alabama; Phoenix, Arizona · 80 sites in all
- Efficacy of TAK-085 in Participants With HypertriglyceridemiaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01350973 · 611 participants · Start Nov 2009 · Primary completion Dec 2010
Drug: Omega-3-acid ethyl esters 90 (TAK-085); Eicosapentaenoic acid-ethyl (EPA-E) · For: Hypertriglyceridemia
- Efficacy of MND-2119 in Participants With HypertriglyceridemiaPivotal-lookingCompleted
Mochida Pharmaceutical Company, Ltd.Industry
NCT03693131 · 580 participants · Start Oct 27, 2018 · Primary completion Jun 15, 2019
Drug: Icosapent (MND-2119); Icosapent (EPADEL CAPSULES 300) · For: Hypertriglyceridemia
Sites: Tokyo, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product odour abnormal1,055
- product physical issue915
- off label use675
- poor quality product administered668
- diarrhoea525
- nausea504
- product taste abnormal451
- drug ineffective450
- arthralgia399
- fatigue350
- blood triglycerides increased305
- eructation281
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 75 |
| 2014 | 102 |
| 2015 | 208 |
| 2016 | 207 |
| 2017 | 350 |
| 2018 | 391 |
| 2019 | 659 |
| 2020 | 939 |
| 2021 | 1,176 |
| 2022 | 801 |
| 2023 | 772 |
| 2024 | 759 |
| 2025 | 952 |
| 2026 | 831 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vascepa (Icosapent Ethyl)
2024 spending
$724M
Beneficiaries
301,070
1,474,990 claims
Per beneficiary
$2,405
$2.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $754,811,701 |
| 2021 | $831,994,328 |
| 2022 | $787,854,458 |
| 2023 | $763,988,447 |
| 2024 | $724,180,334 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Szarek M, Bhatt DL, Miller M, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ, Bhatt DL, Kinninger A, et al. · Eur Heart J 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Verma S, Bhatt DL, Steg PG, et al. · Circulation 2021 · Clinical Trial, Phase III, Multicenter Study
- Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
Miyauchi K, Iwata H, Nishizaki Y, et al. · Circulation 2024 · Randomized Controlled Trial, Multicenter Study
- Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Sayah N, Bhatt DL, Miller M, et al. · Eur Heart J 2024 · Randomized Controlled Trial
Sponsor: Amarin Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.